MET and neoplasm: We first recapitulated the non‐regressed tumours by injecting non‐regressed tumour cells from K and KM tumours into the cleared fat pad of Rag2−/− immunocompromised animals (Fig 5A), and once tumours reached an average of 0.5 cm3, we treated the animals with the cMet inhibitor Tepotinib.